Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids

Abstract Owing to their small size, stable immunoglobulin fold, and ease of production, nanobodies have provided versatile tools for biomedical research and an invaluable protein scaffold for biologics development. In conjunction with genetic code expansion, the applications of nanobodies have been extended to covalent nanobodies, nanobody carriers of radiotracers, and PROTAC chimeras. However, the number of genetically encoded crosslinkers suitable for covalent nanobody development remains limited, and latent crosslinkers with enhanced stability and target-specific reactivity are urgently needed. In this work, we report the incorporation of up to three copies of β-lactam-lysine (BeLaK), a genetically encoded latent crosslinker, at the CDR loops of two EGFR-binding nanobodies following a structure-based design and evaluation of their covalent binding to EGFR in vitro and on the cell surface. To improve the crosslinking efficiency, we investigated two parallel strategies: interfacial protein engineering and biparatopic design. Multiple mutations at the binding interface were well tolerated in terms of EGFR binding affinity, and the biparatopic design raised the affinity by 33−44-fold. However, the crosslinking reactivities of covalent nanobodies, including biparatopic nanobodies, were modest, suggesting that the binding affinity and the crosslinking efficiency are not tightly coupled. One exception was a neighboring residue substitution, E44H, which substantially increased the crosslinking yield, highlighting the local chemical environment as a key determinant of BeLaK reactivity. These results reaffirmed the robust substrate properties of BeLaK in genetic code expansion and the high stability of the encoded proteins in biological systems and uncovered a strategy of interfacial engineering to enhance BeLaK’s latent reactivity after initial target binding.

Authors

Institutions

Publication Details

Journal
ACS Synthetic Biology
Published
2026-11-17
DOI
https://doi.org/10.1021/acssynbio.6c00683
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids

Zheng Wang, Qing Lin, Johnathan D. Rabb, Sabreena Aleem Nabeela
ACS Synthetic Biology
Monoclonal and Polyclonal Antibodies Research
article

Design of Covalent Nanobodies Containing Latent, Genetically Encoded β-Lactam Amino Acids

Zheng Wang, Qing Lin, Johnathan D. Rabb, Sabreena Aleem Nabeela
article en

Abstract

Abstract Owing to their small size, stable immunoglobulin fold, and ease of production, nanobodies have provided versatile tools for biomedical research and an invaluable protein scaffold for biologics development. In conjunction with genetic code expansion, the applications of nanobodies have been extended to covalent nanobodies, nanobody carriers of radiotracers, and PROTAC chimeras. However, the number of genetically encoded crosslinkers suitable for covalent nanobody development remains limited, and latent crosslinkers with enhanced stability and target-specific reactivity are urgently needed. In this work, we report the incorporation of up to three copies of β-lactam-lysine (BeLaK), a genetically encoded latent crosslinker, at the CDR loops of two EGFR-binding nanobodies following a structure-based design and evaluation of their covalent binding to EGFR in vitro and on the cell surface. To improve the crosslinking efficiency, we investigated two parallel strategies: interfacial protein engineering and biparatopic design. Multiple mutations at the binding interface were well tolerated in terms of EGFR binding affinity, and the biparatopic design raised the affinity by 33−44-fold. However, the crosslinking reactivities of covalent nanobodies, including biparatopic nanobodies, were modest, suggesting that the binding affinity and the crosslinking efficiency are not tightly coupled. One exception was a neighboring residue substitution, E44H, which substantially increased the crosslinking yield, highlighting the local chemical environment as a key determinant of BeLaK reactivity. These results reaffirmed the robust substrate properties of BeLaK in genetic code expansion and the high stability of the encoded proteins in biological systems and uncovered a strategy of interfacial engineering to enhance BeLaK’s latent reactivity after initial target binding.

ACS Synthetic Biology
University at Buffalo, State University of New York (US)
National Institute of General Medical Sciences
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon